1. In Vivo

Update Dade: Creating a Dx Consolidator

When Bain Capital created Dade International from Baxter's diagnostics business, it saw Dade as a platform for taking advantage of consolidation in the diagnostics industry. It has lived up to its word.

When Bain Capital created Dade International Inc.from Baxter International Inc. ’s diagnostics business, it saw Dade as a platform for taking advantage of consolidation in the diagnostics industry. It has lived up to its word: In December, Dade announced it was buying the in vitro diagnostics business of DuPont Medical Products.

Although terms of the deal were not disclosed, estimates are that Dade paid $450 to $500 million for the business,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By Jo Shorthouse

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.